Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage

Knijff-Dutmer, Ellen A J; Drossaers-Bakker, Wiepke; Verhoeven, A. C.; Veer, G. van der Sluijs; Boers, Maarten; Linden, S van der; Laar, Mart van de

doi:10.1136/ard.61.7.603

Cited by 25 publications

(15 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several drugs can reduce autoantibody levels in patients with RA, although the extent of these effects varies considerably between drugs and between studies 5–8. High-dose glucocorticoid treatment is relatively safe and reduces IgM-RF levels in patients with RA by more than 50% 5–7. We have made similar unpublished observations regarding ACPA reduction.…”

supporting

confidence: 61%

Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial

et al. 2009

View full text Add to dashboard Cite

show abstract

supporting

confidence: 61%

Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial

et al. 2009

View full text Add to dashboard Cite

show abstract

“…It is well recognized that increased rheumatoid factor serves as a marker of disease activity and inflammation in patients with rheumatoid arthritis, as it is associated with increased concentrations of acute-phase reactants (15 ), disease progression (22,23 ), extraarticular manifestations (24 -26 ), and cardiovascular disease (27)(28)(29). Thus, as systemic inflammation has been linked to development of venous thromboembolism (30 -32 ), increased inflammation in patients with increased rheumatoid factor and/or rheumatoid arthritis is likely to contribute to the increased incidence of venous thromboembolism (2,8 ).…”

Section: Discussionmentioning

confidence: 99%

“…Increased concentrations of rheumatoid factor are present in approximately 70% of patients with rheumatoid arthritis (10 ) and 1%-16% of individuals in the general population (11)(12)(13)(14). In patients with rheumatoid arthritis, increased rheumatoid factor is associated with markers of inflammation and disease activity (15 ). It is presently unknown if increased concentrations of rheumatoid factor is associated with risk of venous thromboembolism.…”

mentioning

confidence: 99%

Increased Rheumatoid Factor and Deep Venous Thrombosis: 2 Cohort Studies of 54628 Individuals from the General Population

2015

View full text Add to dashboard Cite

BACKGROUND The risk of deep venous thrombosis is increased in patients with rheumatoid arthritis. We tested the hypothesis that increased concentrations of rheumatoid factor are associated with increased risk of deep venous thrombosis in individuals without autoimmune rheumatic disease in the general population. METHODS We included 54628 participants from the Copenhagen City Heart Study (1981–83) and the Copenhagen General Population Study (2004–12), all with a measured concentration of IgM rheumatoid factor and without autoimmune rheumatic disease or venous thromboembolism. The main outcome was incident deep venous thrombosis. There were no losses to follow-up. RESULTS During 368381 person-years, 670 individuals developed deep venous thrombosis. A rheumatoid factor concentration ≥ vs <110 IU/mL showed the strongest association with deep venous thrombosis, with multivariable adjusted hazard ratios of 9.0 (95% CI 3.1–26) for 1-year follow-up, 4.3 (2.2–8.5) for 5-year follow-up, and 3.1 (1.7–5.6) for up to 32 years of follow-up. Compared with rheumatoid factor concentrations <15 IU/mL, the multivariable adjusted hazard ratios for deep venous thrombosis during maximum follow-up were 1.3 (1.0–1.5) for 15–29 IU/mL, 1.7 (1.0–2.8) for 30–59 IU/mL, 2.4 (1.3–4.3) for 60–119 IU/mL, and 3.0 (1.6–5.6) for ≥120 IU/mL (trend P = 6 × 10−7). Results were similar in the 2 studies separately. Obese men and women age >60 years with rheumatoid factor concentrations ≥120 IU/mL had 10% and 8% 5-year risk of deep venous thrombosis. CONCLUSIONS Increased rheumatoid factor in the general population was associated with up to 3-fold increased long-term risk and up to 9-fold increased 1-year risk of deep venous thrombosis.

show abstract

“…The biophysical properties of the blood have been measured to effectively monitor disease states or their progresses. Among the biophysical properties, the ESR suggested by Westergren 28 in 1921 has been clinically used to detect infection 24 or inflammatory diseases, including anemia, 29 kidney disease, 30 thyroid disease, 31 rheumatoid arthritis, 32 atherosclerosis, 23 and even cancers. conditions, such as plasma protein level and hematocrit.…”

Section: Introductionmentioning

confidence: 99%

Microfluidic-based measurement of erythrocyte sedimentation rate for biophysical assessment of blood in an in vivo malaria-infected mouse

Kang

Lee

2014

Biomicrofluidics

View full text Add to dashboard Cite

This study suggests a new erythrocyte sedimentation rate (ESR) measurement method for the biophysical assessment of blood by using a microfluidic device. For an effective ESR measurement, a disposable syringe filled with blood is turned upside down and aligned at 180 with respect to gravitational direction. When the blood sample is delivered into the microfluidic device from the top position of the syringe, the hematocrit of blood flowing in the microfluidic channel decreases because the red blood cell-depleted region is increased from the top region of the syringe. The variation of hematocrit is evaluated by consecutively capturing images and conducting digital image processing technique for 10 min. The dynamic variation of ESR is quantitatively evaluated using two representative parameters, namely, time constant (k) and ESR-area (A ESR ). To check the performance of the proposed method, blood samples with various ESR values are prepared by adding different concentrations of dextran solution. k and A ESR are quantitatively evaluated by using the proposed method and a conventional method, respectively. The proposed method can be used to measure ESR with superior reliability, compared with the conventional method. The proposed method can also be used to quantify ESR of blood collected from malaria-infected mouse under in vivo condition. To indirectly compare with the results obtained by the proposed method, the viscosity and velocity of the blood are measured using the microfluidic device. As a result, the biophysical properties, including ESR and viscosity of blood, are significantly influenced by the parasitemia level. These experimental demonstrations support the notion that the proposed method is capable of effectively monitoring the biophysical properties of blood. V C 2014 AIP Publishing LLC. [http://dx

show abstract

Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage

Cited by 25 publications

References 14 publications

Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial

Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial

Increased Rheumatoid Factor and Deep Venous Thrombosis: 2 Cohort Studies of 54628 Individuals from the General Population

Microfluidic-based measurement of erythrocyte sedimentation rate for biophysical assessment of blood in an in vivo malaria-infected mouse

Contact Info

Product

Resources

About